Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Sep 30;58(10):1374.
doi: 10.3390/medicina58101374.

Biomarkers in Alzheimer Disease and Other Dementias: What's Next into Pathophysiology to Support Clinical Practice and Drug Development

Affiliations
Editorial

Biomarkers in Alzheimer Disease and Other Dementias: What's Next into Pathophysiology to Support Clinical Practice and Drug Development

Anastasia Bougea. Medicina (Kaunas). .

Abstract

Neurodegenerative diseases are a heterogeneous group of disorders characterized by gradual progressive neuronal loss in the central nervous system [...].

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

Similar articles

References

    1. Carroll W.M. The global burden of neurological disorders. Lancet Neurol. 2019;18:418–419. doi: 10.1016/S1474-4422(19)30029-8. - DOI - PubMed
    1. Bougea A. Synuclein in neurodegeneration. Adv. Clin. Chem. 2021;103:97–134. - PubMed
    1. Magdalinou N.K., Paterson R.W., Schott J.M., Fox N.C., Mummery C., Blennow K., Bhatia K., Morris H.R., Giunti P., Warner T.T., et al. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J. Neurol. Neurosurg. Psychiatry. 2015;86:1240–1247. doi: 10.1136/jnnp-2014-309562. - DOI - PMC - PubMed
    1. Scarmeas N., Daskalaki A., Kalligerou F., Ntanasi E., Mamalaki E., Gargalionis A.N., Patas K., Chatzipanagiotou S., Yannakoulia M., Constantinides V.C. Initial Data and a Clinical Diagnosis Transition for the Aiginition Longitudinal Biomarker Investigation of Neurodegeneration (ALBION) Study. Medicina. 2022;58:1179. doi: 10.3390/medicina58091179. - DOI - PMC - PubMed
    1. Kern D., Khalil M., Pirpamer L., Buchmann A., Hofer E., Dal-Bianco P., Stögmann E., Scherfler C., Benke T., Ransmayr G., et al. Serum NfL in Alzheimer Dementia: Results of the Prospective Dementia Registry Austria. Medicina. 2022;58:433. doi: 10.3390/medicina58030433. - DOI - PMC - PubMed

Publication types